PDF herunterladen
CC BY-NC-ND 4.0 · Neurology International Open 2018; 02(01): E6-E9
DOI: 10.1055/s-0043-120334
Review
Eigentümer und Copyright ©Georg Thieme Verlag KG 2018

Juvenile Myasthenia Gravis

Adela Della Marina
1   Myasthenie Zentrum für Kinder und Jugendliche, Abteilung für Neuropädiatrie, Kinderklinik I, Universitätsklinikum Duisburg- Essen
,
Ulrike Schara
1   Myasthenie Zentrum für Kinder und Jugendliche, Abteilung für Neuropädiatrie, Kinderklinik I, Universitätsklinikum Duisburg- Essen
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
08. Januar 2018 (online)

   Lizenzen und Reprints

Abstract

Juvenile myasthenia gravis (JMG) is an autoimmune disorder of neuromuscular transmission caused by production of antibodies against the postsynaptic membrane of the neuromuscular junction. Clinical signs in young children and adolescents range from isolated ocular symptoms to general muscular weakness and respiratory insufficiency. Clinical presentation of JMG in young children and adolescents shows distinct features compared to adults. Young children may show generalized muscular weakness already during the first two years of life, and in this group specific antibodies can be only slightly increased. Because of existing therapeutic options, an early diagnosis is important. In case of negative specific antibodies and onset of the first symptoms during infancy or early childhood, the diagnosis of a congenital myasthenic syndrome (CMS) must be considered and is not always clear to differentiate. Clinical symptoms, diagnostic procedures and therapeutic strategies with consideration of specificities of this age group are discussed.

Key words

juvenile myasthenia gravis - clinical symptoms - therapy
 

  • References

  • 1 Popperud TH, Boldingh MI, Brunborg C. et al. Juvenile myasthenia gravis in Norway: A nationwide epidemiological study. Eur J Paediatr Neurol 2017; 21: 312-317
    CrossrefPubMedGoogle Scholar
  • 2 Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve 2009; 39: 423-431
    CrossrefPubMedGoogle Scholar
  • 3 Ashraf VV, Taly AB, Veerendrakumar M. et al. Myasthenia gravis in children: A longitudinal study. Acta Neurol Scand 2006; 114: 119-123
    PubMedGoogle Scholar
  • 4 Evoli A, Batocchi AP, Bartoccioni E. et al. Juvenile myasthenia gravis with prepubertal onset. Neuromuscul Disord 1998; 8: 561-567
    CrossrefPubMedGoogle Scholar
  • 5 Rodriguez M, Gomez MR, Howard Jr FM. et al. Myasthenia gravis in children: long-term follow-up. Ann Neurol 1983; 13: 504-510
    CrossrefPubMedGoogle Scholar
  • 6 Sanders DB. MJ. Clinical features of myasthenia gravis. In: Engel AG. ed. Handb Clin Neurol l. München: Elsevier; 2008: 229-252
    Google Scholar
  • 7 Lindner A, Schalke B, Toyka KV. Outcome in juvenile-onset myasthenia gravis: A retrospective study with long-term follow-up of 79 patients. J Neurol 1997; 244: 515-520
    CrossrefPubMedGoogle Scholar
  • 8 Jaretzki III A, Barohn RJ, Ernstoff RM. et al. Myasthenia gravis recommendations for clinical research standards. Neurology 2000; 55: 16-23
    CrossrefPubMedGoogle Scholar
  • 9 Andrews PI, Massey JM, Howard JF. et al. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 1994; 44: 1208-1214
    CrossrefPubMedGoogle Scholar
  • 10 Batocchi AP, Evoli A, Palmisani MT. et al. Early-onset myasthenia gravis: Clinical characteristics and response to therapy. Eur J Pediatr 1990; 150: 66-68
    CrossrefPubMedGoogle Scholar
  • 11 Zhang X, Yang M, Xu J. et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 2007; 78: 386-390
    PubMedGoogle Scholar
  • 12 Hong Y, Skeie GO, Zisimopoulou P. et al. Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms. J Neurol 2017; 264: 955-962
    CrossrefPubMedGoogle Scholar
  • 13 Schara U, Schneider-Gold C, Schrank B. Klinik und Transition neuromuskulärer Erkrankungen. 1. Aufl. Heidelberg: Springer; 2015
    Google Scholar
  • 14 Schara U, Della Marina A, Abicht A. Congenital myasthenic syndromes: Current diagnostic and therapeutic approaches. Neuropediatrics 2012; 43: 184-193
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 AWMF. S2k Leitlinie 030-087: Myasthenia gravis und Lambert-Eaton-Syndrom, Diagnostik und Therapie 2014;www.awmf.org
    PubMed
  • 16 Ionita CM, Acsadi G. Management of Juvenile myasthenia gravis. Pediatr Neurol 2013; 48: 95-104
    CrossrefPubMedGoogle Scholar
  • 17 Heng HS, Lim M, Absoud M. et al. Outcome of children with acetylcholine receptor (AChR) antibody positive juvenile myasthenia gravis following thymectomy. Neuromuscul Disord 2014; 24: 25-30
    CrossrefPubMedGoogle Scholar
  • 18 Castro D, Derisavifard S, Anderson M. et al. Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis 2013; 14: 95-102
    CrossrefPubMedGoogle Scholar
  • 19 Koul R, Al Futaisi A, Abdwani R. Rituximab in severe seronegative juvenile myasthenia gravis: Review of the literature. Pediatr Neurol 2012; 47: 209-212
    CrossrefPubMedGoogle Scholar
  • 20 Tzaribachev N, Koetter I, Kuemmerle-Deschner JB. et al. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2009; 2: 6609
    CrossrefPubMedGoogle Scholar
  • 21 Della Marina A, Kölbel H, Müllers M. et al. Outcome after robotic-assisted thymectomy in children and adolescents with acetylcholine receptor antibody-positive juvenile myasthenia gravis. Neuropediatrics 2017; 48: 315-322
    Artikel in Thieme ConnectPubMedGoogle Scholar